Xilio Therapeutics (NASDAQ:XLO) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Xilio Therapeutics (NASDAQ:XLO) released its earnings results on Tuesday. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.08, FiscalAI reports. The company had revenue of $12.65 million during the quarter, compared to analysts’ expectations of $8.52 million. Xilio Therapeutics had a negative net margin of 80.05% and a negative return on equity of 393.01%.

Xilio Therapeutics Trading Up 1.8%

Shares of NASDAQ XLO traded up $0.14 during mid-day trading on Tuesday, reaching $7.87. 10,700 shares of the company’s stock were exchanged, compared to its average volume of 36,289. The business has a fifty day simple moving average of $8.05 and a 200 day simple moving average of $9.01. Xilio Therapeutics has a twelve month low of $6.47 and a twelve month high of $16.52. The firm has a market capitalization of $47.08 million, a price-to-earnings ratio of -1.43 and a beta of -0.16.

Analyst Upgrades and Downgrades

XLO has been the topic of several analyst reports. Wall Street Zen raised shares of Xilio Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Weiss Ratings raised shares of Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Institutional Investors Weigh In On Xilio Therapeutics

Several hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC boosted its stake in Xilio Therapeutics by 39.6% in the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock valued at $277,000 after purchasing an additional 93,338 shares during the period. Renaissance Technologies LLC increased its holdings in Xilio Therapeutics by 68.3% in the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock worth $220,000 after purchasing an additional 139,716 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Xilio Therapeutics in the fourth quarter valued at about $27,000. State Street Corp boosted its position in shares of Xilio Therapeutics by 13.7% during the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after purchasing an additional 22,500 shares in the last quarter. Finally, Velan Capital Investment Management LP bought a new position in Xilio Therapeutics in the fourth quarter worth approximately $109,000. 54.29% of the stock is currently owned by institutional investors and hedge funds.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.